<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
OCTOBER 27, 2000
---------------------------------------------------
Date of Report (Date of earliest event reported)
INHALE THERAPEUTIC SYSTEMS, INC.
---------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 023556 94-3134940
------------------------------ ------------------ ------------------------
(State or other (Commission (I.R.S. Employer
jurisdiction of incorporation) File Number) Identification No.)
150 Industrial Road
San Carlos, CA 94070
---------------------------------------------------
(Address of principal executive offices)
(650) 631-3100
---------------------------------------------------
(Registrant's telephone number, including area code)
---------------------------------------------------
(Former name, if changed since last report)
<PAGE>
ITEM 5. OTHER EVENTS
On October 27, 2000, Inhale Therapeutic Systems, Inc. announced that
the initial purchasers have exercised their $30 million over-allotment option
granted pursuant to a purchase agreement dated October 11, 2000 with respect to
the Company's 3.5% convertible subordinated notes due 2007. The closing of the
over-allotment increases the aggregate principal amount of convertible
subordinated notes to $230 million. A press release relating to the issuance is
attached hereto as Exhibit 99.1.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS
(c) Exhibits
99.1 Press Release dated October 27, 2000
2.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
INHALE THERAPEUTIC SYSTEMS, INC.
Dated: October 30, 2000 By:/s/ Brigid A. Makes
-------------------------------
Brigid A. Makes,
Chief Financial Officer and
Vice President,
Finance and Administration
3.
